Gilead Sciences 3Q Revenues: $6.6 billion (+17%) 3Q Earnings: $360 million (earnings were $1.2 billion 3Q19) YTD Revenues: $17.3 billion (+4%) YTD Loss: $1.4 billion (earnings were $2.7 billion YTD19) Comments: HIV Product sales were $4.5 billion, up 8% primarily due to the continued strength of the HIV franchise and Biktarvy share continues to grow in the U.S. HCV Product sales declined 31% to $464 million impacted by delayed patient starts due to the COVID-19 pandemic and l...